Application Note

Cell Line Development: Accelerating Antibody Discovery With The Octet® Platform

Source: Sartorius

By Hongshan Li

iStock-1180568371-antibody-3D

Cell line development involves multiple processes. Large numbers of clones are screened and selected on the basis of productivity and stability. Octet® systems have been an established platform for rapid titer of antibody clones to enable quick selection of high-producing clones. Combined with the Octet® Sialic Acid (GlyS) and Octet® Mannose (GlyM) kit assays, cell line development scientists can also screen for the relative terminal sialic acid content in crude or purified samples to better select optimal clones that are both high producers and have desirable sialic acid content.

VIEW THE APPLICATION NOTE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Drug Discovery Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: